Cover Image
Market Research Report

Hyperlipidemia Drug Market 2019-2025

Published by Orion Market Research Pvt Ltd Product code 949570
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Hyperlipidemia Drug Market 2019-2025
Published: June 12, 2020 Content info:
Description

Global Hyperlipidemia Drug Market Size, Share & Trends Analysis Report, By Drug Class (HMG-CoA Reductase Inhibitors (Statins), PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fabric Acid Derivatives (Fibrates), Niacin (Nicotinic Acid), Bile Acid Sequestrants(BAS), Combination Therapy, and Others) and Forecast Period 2019-2025

The global hyperlipidemiadrug market is estimated to grow at a low CAGR during the forecast period.The increasing number of cholesterol patients is propelling the global hyperlipidemiadrug market. As per WHO, hypercholesterolemia is estimated to result in more than 2.6 million deaths each year. Almost 37.0% of adults in the US have high LDL-C levels. Yet, lesser than 50.0% of patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels.However, the side effects of hyperlipidemia drugs are restraining the growth of the market.

The global hyperlipidemia drug market is segmented based on the drug class. Based on the drug class the market is segmented into HMG-CoA reductase inhibitors (statins), PCSK9 inhibitors, cholesterol absorption inhibitors, fabric acid derivatives (fibrates), niacin (nicotinic acid), bile acid sequestrants(BAS), combination therapy and others.Geographically, theglobal hyperlipidemiadrug market is segmented based on the region including North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

The major manufactures of the hyperlipidemiadrug includeAmgen Inc.,Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc., Mylan N.V, GlaxoSmithKline PLC Pfizer, Inc.,Sanofi-Aventis S.A.,Merck & Co., Inc.,Dr.Reddy's Laboratories, Ltd. and others.These companies are continuously making efforts to provide innovative products in the market.For instance, in April 2019, TtheUS FDA also approved Sanofi's Praluent. It is used as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.

Research Methodology

The market study of the global hyperlipidemiadrug market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of hyperlipidemia drugs, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

Market Segmentation-

  • Global HyperlipidemiaDrugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global hyperlipidemiadrug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global hyperlipidemiadrug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
Table of Contents
Product Code: OMR2021889

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novartis AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Mylan N.V.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Pfizer, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sanofi-Aventis S.A.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Hyperlipidemia Drug Marketby Drug Class
    • 5.1.1. HMG-CoA Reductase Inhibitors (Statins)
    • 5.1.2. PCSK9 Inhibitors
    • 5.1.3. Cholesterol Absorption Inhibitors
    • 5.1.4. Fabric Acid Derivatives (Fibrates)
    • 5.1.5. Niacin (Nicotinic Acid)
    • 5.1.6. Bile Acid Sequestrants(BAS)
    • 5.1.7. Combination Therapy
    • 5.1.8. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amgen, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Bristol-Myers Squibb Co.
  • 7.5. Daiichi Sankyo Co., Ltd.
  • 7.6. Dr.Reddy's Laboratories, Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Ionis Pharmaceuticals, Inc.
  • 7.9. Merck & Co., Inc.
  • 7.10. Mylan N.V.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc.
  • 7.13. Sanofi-Aventis S.A.
  • 7.14. Sun Pharmaceutical Industries, Ltd.
  • 7.15. Teva Pharmaceutical Industries, Ltd.

LIST OF TABLES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 2. GLOBALHMG-COA REDUCTASE INHIBITORS (STATINS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 3. GLOBAL PCSK9 INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 4. GLOBAL CHOLESTEROL ABSORPTION INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 5. GLOBAL FABRIC ACID DERIVATIVES (FIBRATES)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 6. GLOBAL NIACIN (NICOTINIC ACID)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 7. GLOBAL BILE ACID SEQUESTRANTS(BAS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 8. GLOBAL COMBINATION THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 9. GLOBAL OTHERSHYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 10. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN HYPERLIPIDEMIADRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 14. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BYDRUG CLASS, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BYDRUG CLASS, 2018 VS 2025 (%)
  • 2. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
Back to Top